Out­look to con­duct an­oth­er tri­al for wet AMD drug; Cara strikes new roy­al­ty deal

Out­look to con­duct an­oth­er tri­al for eye drug af­ter re­jec­tion: Out­look Ther­a­peu­tics an­nounced Thurs­day that the FDA wants an ad­di­tion­al study as­sess­ing be­va­cizum­ab in wet age-re­lat­ed mac­u­lar de­gen­er­a­tion. The com­pa­ny had re­ceived a com­plete re­sponse let­ter in Au­gust, with the reg­u­la­tor cit­ing “sev­er­al CMC is­sues, open ob­ser­va­tions from pre-ap­proval man­u­fac­tur­ing in­spec­tions and a lack of sub­stan­tial ev­i­dence.” It now plans to re­sub­mit the ap­pli­ca­tion in late 2024, aim­ing for an ap­proval in mid-2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER